top of page
Search

The Amos Case and Medical Governance: When Debate Becomes Risky for Doctors practicing Paediatric Gender Medicine.

  • Mark Neugebauer - FCP Australia
  • Mar 9
  • 6 min read

Updated: Mar 10



The regulatory action against psychiatrist Andrew Amos raises broader questions about AHPRA, scientific debate, and the governance of paediatric gender medicine in Australia.



In a recent article, When Evidence Shifts, Silence Is Not Neutral, I explained why I had written to South Australian political representatives requesting a precautionary pause on new prescriptions of puberty blockers for minors while safeguarding continuity of care for existing patients.


The request was narrow and principled.


It did not seek to end care for gender-distressed young people.

It did not accuse clinicians of wrongdoing.

And it did not attempt to settle a complex medical debate.


Rather, it asked a simpler question:

When the evidence base for a medical intervention involving children is actively being reassessed internationally, how should governments respond?


Since that article was published, a related issue has emerged that raises a second question about medical governance in Australia.


Not only how governments respond to uncertainty, but whether doctors are able to discuss that uncertainty openly.


Recently the Australian Health Practitioner Regulation Agency (AHPRA) imposed conditions on Queensland psychiatrist Dr Andrew Amos, restricting aspects of his clinical practice and limiting his ability to publicly comment on gender medicine.


The restrictions followed complaints about Dr Amos’s public commentary questioning the evidence base for puberty blockers and cross-sex hormones for minors.


AHPRA’s “immediate action” powers allow regulators to impose conditions where they believe there may be a serious risk to public health or safety, even before a full investigation is completed.


Regulators exist for an important reason: to protect patients.


But when regulatory action intersects with scientific debate, the implications extend beyond one clinician.


They raise a broader question about how medicine handles contested evidence.



Scientific progress depends on open debate

Medicine does not advance through consensus alone, it advances through evidence, challenge, reassessment, and sometimes disagreement.


Clinicians question existing practices, researchers test assumptions, new data alters previous understandings.


This process is not a flaw in medicine, It's the reason medicine improves.

In areas of settled science, debate tends to narrow naturally, but in areas where evidence is incomplete, evolving, or contested, debate becomes even more important.


This is particularly true when medical interventions involve children and may carry long-term or irreversible consequences.


International reassessment of paediatric gender medicine

Over the past several years, paediatric gender medicine has undergone significant reassessment internationally. (see links at end for further reading)


The Cass Review in the United Kingdom identified substantial weaknesses in the evidence base supporting puberty blockers and cross-sex hormones for minors.


Nordic health authorities in Sweden and Finland have restricted such treatments primarily to research settings or exceptional cases.


New Zealand has paused new prescriptions of puberty blockers while evidence reviews are conducted.


These developments do not represent hostility toward gender-diverse young people.

Rather, they reflect a growing recognition that the long-term evidence surrounding these treatments remains limited and that stronger governance and research frameworks are required.


When evidence is being reassessed internationally, it is natural, and responsible for clinicians to examine the issue closely.


A record of correspondence

Over the past two years I have written to state and federal representatives regarding the governance of paediatric gender medicine in South Australia. These letters were not written as part of a campaign but as an attempt to raise concerns through normal democratic channels.


They are published here as primary source material so readers can examine the dialogue directly.


In March 2024 I wrote to the Premier of South Australia asking why members of the governing party had been denied a conscience vote on a proposed parliamentary inquiry into gender identity practices.


The correspondence raised concerns about emerging international evidence regarding the “affirmative care” model and encouraged the government to allow a parliamentary examination of the issue.


A follow-up letter was sent shortly afterwards highlighting developments in the United Kingdom, where the NHS had begun restricting the use of puberty blockers for minors pending further review.


The letter asked whether similar scrutiny of paediatric gender medicine would occur in South Australia.


In November 2025 I wrote to the Premier, Health Minister, and Child Protection Minister requesting a temporary pause on new prescriptions of puberty blockers for minors, while explicitly safeguarding continuity of care for children already receiving treatment.

The letter argued that significant policy shifts in the United Kingdom, New Zealand, and Queensland suggested growing international caution regarding puberty-blocking medications for children.


The proposal included several safeguards:

  • a time-limited pause on new prescriptions

  • protection for existing patients

  • an independent review of South Australian practices

  • improved reporting of treatment numbers and outcomes


In response, the South Australian Minister for Health and Wellbeing stated that medical decisions should be made by doctors rather than politicians and noted that a national review of gender treatment guidelines was underway through the National Health and Medical Research Council (NHMRC).


A further letter sought clarification on several unresolved issues, including whether South Australia had conducted its own audit of paediatric gender services and whether interim precautionary measures would be considered while the national review is underway.


The correspondence also asked whether treatment outcomes, adverse events, and long-term follow-up data were being systematically collected and publicly reported.


More recently I wrote to the Federal Minister for Health and the South Australian Health Minister raising concerns about regulatory actions affecting clinicians who publicly question aspects of paediatric gender medicine.


That correspondence asked whether Australia’s medical regulatory framework adequately protects good-faith scientific debate when treatments affecting children are under active international review.


Lessons from recent years

The recent regulatory actions involving Dr Andrew Amos, and concerns raised by other clinicians such as psychiatrist Dr Jillian Spencer, intersect with a broader issue that has been raised repeatedly in this correspondence.


When emerging treatments affecting children are under active international review, it is vital that clinicians are able to raise questions about evidence, risks, and long-term outcomes without fear that professional debate itself will trigger disciplinary action.

This question is not entirely new.


During the COVID-19 period, a number of Australian clinicians (e.g. AMA president Dr Kerryn Phelps, Infectious diseases physician Professor Peter Collignon, Emeritus professor of immunology Robert Clancy, Former Deputy Chief Medical Officer Dr Nick Coatsworth to name a few), expressed concern that professional regulatory settings were discouraging open discussion about evolving evidence and policy decisions.


Whether or not those concerns were well founded, the experience demonstrated how regulatory environments, even when acting with good intentions, can unintentionally narrow professional debate in areas where scientific uncertainty still exists.


Why this matters for public trust

Public confidence in medicine depends on more than regulatory enforcement.

It depends on transparency, it depends on intellectual humility, and it depends on the willingness of institutions to allow evidence to be examined openly, even when that examination is uncomfortable.


When complex medical questions involving children are under active review around the world, the public should be able to trust that Australian clinicians can discuss those questions freely and responsibly.


Healthy scientific disagreement is not a threat to medicine.

In many cases, it is the mechanism through which medicine protects patients and improves care.


The question moving forward

The issue raised by the Amos case is therefore not about one doctor, it is about whether Australia’s medical regulatory environment continues to support open, evidence-based discussion in areas where scientific uncertainty remains.


For treatments involving children, where decisions may carry lifelong consequences, that question deserves careful attention.


In medicine, silence is not always neutrality, sometimes the most responsible course is to ensure that difficult questions can still be asked.



For readers interested in the wider public debate, the Australian Christian Lobby has launched a petition calling for the restrictions on Dr Andrew Amos to be lifted, arguing that doctors should be able to participate in scientific discussion without professional sanction. The petition can be accessed here:


Useful links for further reading, research, and your own discernment.










Comments

Rated 0 out of 5 stars.
No ratings yet
Add a rating

COPYRIGHT - 2026 FAITH CULTURE POLITICS AUSTRALIA 

  • Youtube
  • Facebook
  • X
  • TikTok
bottom of page